These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35034207)

  • 1. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.
    Leatherdale A; Stukas S; Lei V; West HE; Campbell CJ; Hoiland RL; Cooper J; Wellington CL; Sekhon MS; Pryzdial ELG; Conway EM
    Med Microbiol Immunol; 2022 Feb; 211(1):37-48. PubMed ID: 35034207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
    Sinkovits G; Mező B; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Front Immunol; 2021; 12():663187. PubMed ID: 33841446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
    Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
    Front Immunol; 2022; 13():946522. PubMed ID: 36091057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
    Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
    J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.
    Meroni PL; Croci S; Lonati PA; Pregnolato F; Spaggiari L; Besutti G; Bonacini M; Ferrigno I; Rossi A; Hetland G; Hollan I; Cugno M; Tedesco F; Borghi MO; Salvarani C
    Autoimmun Rev; 2023 Jan; 22(1):103232. PubMed ID: 36414219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of complement pathways with COVID-19 severity and outcomes.
    Devalaraja-Narashimha K; Ehmann PJ; Huang C; Ruan Q; Wipperman MF; Kaplan T; Liu C; Afolayan S; Glass DJ; Mellis S; Yancopoulos GD; Hamilton JD; MacDonnell S; Hamon SC; Boyapati A; Morton L
    Microbes Infect; 2023 May; 25(4):105081. PubMed ID: 36494054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study.
    Charitos P; Heijnen IAFM; Egli A; Bassetti S; Trendelenburg M; Osthoff M
    Front Immunol; 2021; 12():765330. PubMed ID: 34777382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.
    Siggins MK; Davies K; Fellows R; Thwaites RS; Baillie JK; Semple MG; Openshaw PJM; Zelek WM; Harris CL; Morgan BP;
    Immunology; 2023 Mar; 168(3):473-492. PubMed ID: 36175370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
    Cugno M; Meroni PL; Gualtierotti R; Griffini S; Grovetti E; Torri A; Lonati P; Grossi C; Borghi MO; Novembrino C; Boscolo M; Uceda Renteria SC; Valenti L; Lamorte G; Manunta M; Prati D; Pesenti A; Blasi F; Costantino G; Gori A; Bandera A; Tedesco F; Peyvandi F
    J Autoimmun; 2021 Jan; 116():102560. PubMed ID: 33139116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study.
    Bruni F; Charitos P; Lampart M; Moser S; Siegemund M; Bingisser R; Osswald S; Bassetti S; Twerenbold R; Trendelenburg M; Rentsch KM; Osthoff M
    Front Immunol; 2022; 13():941742. PubMed ID: 36203596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients.
    Dupont T; Caillat-Zucman S; Fremeaux-Bacchi V; Morin F; Lengliné E; Darmon M; Peffault de Latour R; Zafrani L; Azoulay E; Dumas G
    Chest; 2021 May; 159(5):1884-1893. PubMed ID: 33316234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
    Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
    Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement Activation in Kidneys of Patients With COVID-19.
    Pfister F; Vonbrunn E; Ries T; Jäck HM; Überla K; Lochnit G; Sheriff A; Herrmann M; Büttner-Herold M; Amann K; Daniel C
    Front Immunol; 2020; 11():594849. PubMed ID: 33584662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial.
    Lim EHT; Vlaar APJ; Bos LDJ; van Vught LA; Boer AMT; Dujardin RWG; Habel M; Xu Z; Brouwer MC; van de Beek D; de Bruin S;
    Respir Res; 2022 Dec; 23(1):375. PubMed ID: 36566174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.
    de Nooijer AH; Grondman I; Janssen NAF; Netea MG; Willems L; van de Veerdonk FL; Giamarellos-Bourboulis EJ; Toonen EJM; Joosten LAB;
    J Infect Dis; 2021 Feb; 223(2):214-224. PubMed ID: 33038254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID.
    Baillie K; Davies HE; Keat SBK; Ladell K; Miners KL; Jones SA; Mellou E; Toonen EJM; Price DA; Morgan BP; Zelek WM
    Med; 2024 Mar; 5(3):239-253.e5. PubMed ID: 38359836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe COVID-19 is associated with hyperactivation of the alternative complement pathway.
    Boussier J; Yatim N; Marchal A; Hadjadj J; Charbit B; El Sissy C; Carlier N; Pène F; Mouthon L; Tharaux PL; Bergeron A; Smadja DM; Rieux-Laucat F; Duffy D; Kernéis S; Frémeaux-Bacchi V; Terrier B
    J Allergy Clin Immunol; 2022 Feb; 149(2):550-556.e2. PubMed ID: 34800432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.
    Peerschke EI; Valentino A; So RJ; Shulman S; Ravinder
    Front Immunol; 2021; 12():716361. PubMed ID: 34491250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.
    Vachino G; Gelfand JA; Atkins MB; Tamerius JD; Demchak P; Mier JW
    Blood; 1991 Nov; 78(10):2505-13. PubMed ID: 1824247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.